2015
DOI: 10.1016/j.lfs.2015.10.023
|View full text |Cite
|
Sign up to set email alerts
|

Chronic effects of losartan on the muscles and the serologic profiles of mdx mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
28
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 27 publications
(29 citation statements)
references
References 24 publications
1
28
0
Order By: Relevance
“…Serum-based enzyme tests have been widely used for various applications in the clinic [ 33 – 35 ]. And a variety of serum enzymes, such as CK, ALT, and AST, were reported to increase in muscular dystrophy [ 36 , 37 ]. The elevation of serum enzymes in dystrophinopathy is thought to be due to their release from injured myofibers rather than to liver injury as indicated by liver biopsy in patients [ 38 ].…”
Section: Discussionmentioning
confidence: 99%
“…Serum-based enzyme tests have been widely used for various applications in the clinic [ 33 – 35 ]. And a variety of serum enzymes, such as CK, ALT, and AST, were reported to increase in muscular dystrophy [ 36 , 37 ]. The elevation of serum enzymes in dystrophinopathy is thought to be due to their release from injured myofibers rather than to liver injury as indicated by liver biopsy in patients [ 38 ].…”
Section: Discussionmentioning
confidence: 99%
“…ACE inhibitors have been suggested to protect muscle function in older people, although more recent prospective studies did not confirm this association [23,24]. There is some experimental evidence that ARBs may be beneficial to muscle function in a deconditioned animal model [25,26]. However, the effect of ARB has not been reported in human muscle.…”
Section: Discussionmentioning
confidence: 99%
“…Multiple studies aimed at modulating the mdx phenotype have pointed to angiotensin-related signaling pathways and oxidative stress as important factors in both the skeletal and cardiac phenotype of dystrophic mice [26][27][28][29][30][31]. Importantly, drugs including ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), and antioxidants have shown a significant benefit for dystrophic mice and human patients [22,[32][33][34][35][36][37][38]. Current recommendations guide clinicians to consider initiating ACEi or ARB therapy at the age of 10 in Duchenne patients even without cardiac symptoms.…”
Section: Introductionmentioning
confidence: 99%